

In the Claims:

Please cancel claims 86-90 without any prejudice and disclaimer.

Please replace claim 85 with the following clean set of amended claim 85. A mark-up version of the amended claim 85 is attached hereto as Exhibit A.

85. (Amended) A method of preparing an immunogenic composition, comprising the steps of:

- D1
- (a) providing an autologous target tumor or pathogen infected cell;
 - (b) treating the tumor or pathogen infected cell with a cytokine to increase concentration of a primary T cell activation molecule or a costimulatory T cell activation molecule in the target tumor or pathogen infected cell;
 - (c) providing a bispecific monoclonal antibody including one or more binding sites for one or more costimulatory molecules on a surface of one or more T cells of a patient mammal;
 - (d) attaching the bispecific monoclonal antibody to the target tumor or pathogen infected cell; and
 - (e) collecting a pharmaceutically effective amount of the target tumor or pathogen infected cell with the attached bispecific monoclonal antibody.
-

Please add new claims 91-100 as follows:

91. (New) The method of claim 85, wherein an autologous target tumor cell is provided.

D2

92. (New) The method of claim 91, wherein the tumor cell is selected from the group consisting of a hepatocellular carcinoma cell, a lymphoma cell, a colon carcinoma cell and a gastric cancer cell.

93. (New) The method of claim 85, wherein the cytokine is IFN- γ and/or TNF- α .

94. (New) The method of claim 85, wherein the T cell is selected from the group consisting of a CD3+, a CD8+ and a CD25+ T cell.

95. (New) The method of claim 85, wherein the costimulatory T cell activation molecule is CD28 or 4-1BB molecule.

96. (New) The method of claim 85, wherein the bispecific monoclonal antibody is a CD28:gp115 or CD28:gp55 bispecific monoclonal antibody.

97. (New) The method of claim 85, wherein the bispecific monoclonal antibody includes two or more binding sites for two or more costimulatory molecules on a surface of one or more T cells of a patient mammal.

98. (New) The method of claim 85, wherein the patient mammal is a human.

99. (New) The method of claim 85, further comprising removing the bispecific monoclonal antibody not attached to the target tumor or pathogen infected cell before step (e).

100. (New) A method of preparing an immunogenic composition, comprising the steps of:

- (a) providing an autologous target tumor cell;
 - (b) treating the tumor cell with IFN- γ and/or TNF- α to increase concentration of CD28 in the target tumor cell;
 - (c) providing a CD28:gp115 or CD28:gp55 bispecific monoclonal antibody;
 - (d) attaching the CD28:gp115 or CD28:gp55 bispecific monoclonal antibody to the target tumor cell; and
 - (e) collecting a pharmaceutically effective amount of the target tumor cell with the attached CD28:gp115 or CD28:gp55 bispecific monoclonal antibody.
-